Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib

IF 2.4 Q2 RESPIRATORY SYSTEM

Respiratory investigation Pub Date : 2025-03-18 DOI:10.1016/j.resinv.2025.03.006

Yasuhiko Koga , Mitsuru Motegi , Akihiro Ono , Yoshimasa Hachisu , Mitsuyoshi Utsugi , Noriaki Sunaga , Atsushi Takise , Mari Sato , Tomohito Kuwako , Takashi Osaki , Manabu Ueno , Seishi Yoshimi , Koichi Yamaguchi , Takeshi Hisada , Kyoichi Kaira

{"title":"Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib","authors":"Yasuhiko Koga , Mitsuru Motegi , Akihiro Ono , Yoshimasa Hachisu , Mitsuyoshi Utsugi , Noriaki Sunaga , Atsushi Takise , Mari Sato , Tomohito Kuwako , Takashi Osaki , Manabu Ueno , Seishi Yoshimi , Koichi Yamaguchi , Takeshi Hisada , Kyoichi Kaira","doi":"10.1016/j.resinv.2025.03.006","DOIUrl":null,"url":null,"abstract":"<div><div>Both serum and bronchoalveolar lavage fluid levels of galectin-3 (Gal-3) are elevated in patients with idiopathic pulmonary fibrosis (IPF). Phase II study on inhaler with Gal-3 inhibitor for IPF has been ongoing. In this study, 30 treatment-naive patients of IPF were prospectively enrolled and their sera were stored before and after nintedanib treatment. Though Gal-3 levels tended to increase after nintedanib treatment, in some patients, Gal-3 levels decreased immediately after the treatment. Patients whose serum Gal-3 levels decreased 1 month after nintedanib treatment tended to experience a smaller annual decline in forced vital capacity (FVC) than patients with increased Gal-3 levels. Furthermore, the rate of change in Gal-3 levels 1 month after nintedanib treatment positively correlated with the rate of annual FVC decline, whereas that of other fibrotic markers did not correlate with the rate of annual FVC decline.</div><div>This study suggested that a decline in serum Gal-3 levels immediately after nintedanib treatment may predict less progression of IPF treated with nintedanib.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 394-398"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534525000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Both serum and bronchoalveolar lavage fluid levels of galectin-3 (Gal-3) are elevated in patients with idiopathic pulmonary fibrosis (IPF). Phase II study on inhaler with Gal-3 inhibitor for IPF has been ongoing. In this study, 30 treatment-naive patients of IPF were prospectively enrolled and their sera were stored before and after nintedanib treatment. Though Gal-3 levels tended to increase after nintedanib treatment, in some patients, Gal-3 levels decreased immediately after the treatment. Patients whose serum Gal-3 levels decreased 1 month after nintedanib treatment tended to experience a smaller annual decline in forced vital capacity (FVC) than patients with increased Gal-3 levels. Furthermore, the rate of change in Gal-3 levels 1 month after nintedanib treatment positively correlated with the rate of annual FVC decline, whereas that of other fibrotic markers did not correlate with the rate of annual FVC decline.

This study suggested that a decline in serum Gal-3 levels immediately after nintedanib treatment may predict less progression of IPF treated with nintedanib.

查看原文本刊更多论文

血清半乳糖凝集素-3作为尼达尼治疗特发性肺纤维化进展的生物标志物

特发性肺纤维化（IPF）患者血清和支气管肺泡灌洗液中半乳糖凝集素-3 （Gal-3）水平升高。含Gal-3抑制剂的IPF吸入器的II期研究正在进行中。在这项研究中，前瞻性地招募了30例初次治疗的IPF患者，并在尼达尼布治疗前后保存了他们的血清。虽然在尼达尼布治疗后Gal-3水平有升高的趋势，但在一些患者中，Gal-3水平在治疗后立即下降。尼达尼布治疗1个月后血清Gal-3水平下降的患者，其强迫肺活量（FVC）的年下降幅度小于Gal-3水平升高的患者。此外，尼达尼布治疗1个月后，Gal-3水平的变化率与FVC年递减率呈正相关，而其他纤维化标志物的变化率与FVC年递减率无关。这项研究表明，在尼达尼治疗后立即降低血清Gal-3水平可能预示着尼达尼治疗IPF的进展较少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊